284 related articles for article (PubMed ID: 27535751)
1. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
[TBL] [Abstract][Full Text] [Related]
2. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels.
Gautier-Veyret E; Fonrose X; Tonini J; Thiebaut-Bertrand A; Bartoli M; Quesada JL; Bulabois CE; Cahn JY; Stanke-Labesque F
Antimicrob Agents Chemother; 2015 Apr; 59(4):2305-14. PubMed ID: 25645831
[TBL] [Abstract][Full Text] [Related]
3. A prospective feasibility study of primary prophylaxis against invasive fungal disease with voriconazole following umbilical cord blood transplantation with fludarabine-based conditioning.
Takagi S; Araoka H; Uchida N; Uchida Y; Kaji D; Ota H; Nishida A; Ishiwata K; Tsuji M; Yamamoto H; Ito T; Matsuno N; Yamamoto G; Asano-Mori Y; Hayashi M; Izutsu K; Masuoka K; Wake A; Makino S; Yoneyama A; Taniguchi S
Int J Hematol; 2014; 99(5):652-8. PubMed ID: 24664791
[TBL] [Abstract][Full Text] [Related]
4. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
6. Comparison of long-term and short-term administration of itraconazole for primary antifungal prophylaxis in recipients of allogeneic hematopoietic stem cell transplantation: a multicenter, randomized, open-label trial.
Lin R; Xu X; Li Y; Sun J; Fan Z; Jiang Q; Huang F; Zhou H; Nie D; Guo Z; Mao Y; Xiao Y; Liu Q
Transpl Infect Dis; 2014 Apr; 16(2):286-94. PubMed ID: 24593273
[TBL] [Abstract][Full Text] [Related]
7. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 Genotype and Liver Function on Voriconazole Pharmacokinetics in Renal Transplant Recipients.
Li ZW; Peng FH; Yan M; Liang W; Liu XL; Wu YQ; Lin XB; Tan SL; Wang F; Xu P; Fang PF; Liu YP; Xiang DX; Zhang BK
Ther Drug Monit; 2017 Aug; 39(4):422-428. PubMed ID: 28604474
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.
Montesinos P; Rodríguez-Veiga R; Boluda B; Martínez-Cuadrón D; Cano I; Lancharro A; Sanz J; Arilla MJ; López-Chuliá F; Navarro I; Lorenzo I; Salavert M; Pemán J; Calvillo P; Martínez J; Carpio N; Jarque I; Sanz GF; Sanz MA
Bone Marrow Transplant; 2015 Nov; 50(11):1465-72. PubMed ID: 26281032
[TBL] [Abstract][Full Text] [Related]
10. Experience with anidulafungin in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease.
Yáñez L; Insunza A; Ibarrondo P; de Miguel C; Bermúdez A; Colorado M; López-Duarte M; Richard C; Conde E
Transpl Infect Dis; 2015 Oct; 17(5):761-7. PubMed ID: 26250790
[TBL] [Abstract][Full Text] [Related]
11. Inflammation is a potential risk factor of voriconazole overdose in hematological patients.
Gautier-Veyret E; Truffot A; Bailly S; Fonrose X; Thiebaut-Bertrand A; Tonini J; Cahn JY; Stanke-Labesque F
Fundam Clin Pharmacol; 2019 Apr; 33(2):232-238. PubMed ID: 30306637
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients.
Brüggemann RJ; Blijlevens NM; Burger DM; Franke B; Troke PF; Donnelly JP
J Antimicrob Chemother; 2010 Jan; 65(1):107-13. PubMed ID: 19933691
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.
Guinea J; Escribano P; Marcos-Zambrano LJ; Peláez T; Kestler M; Muñoz P; Vena A; López-Fabal F; Bouza E
Med Mycol; 2016 May; 54(4):353-60. PubMed ID: 26739190
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients.
Mori T; Aisa Y; Kato J; Nakamura Y; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2009 Sep; 44(6):371-4. PubMed ID: 19270729
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients.
Imataki O; Yamaguchi K; Uemura M; Fukuoka N
Transpl Infect Dis; 2018 Aug; 20(4):e12886. PubMed ID: 29570914
[TBL] [Abstract][Full Text] [Related]
16. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.
Ceberio I; Dai K; Devlin SM; Barker JN; Castro-Malaspina H; Goldberg JD; Giralt S; Adel NG; Perales MA
Bone Marrow Transplant; 2015 Mar; 50(3):438-43. PubMed ID: 25599164
[TBL] [Abstract][Full Text] [Related]
17. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients.
Trifilio S; Pennick G; Pi J; Zook J; Golf M; Kaniecki K; Singhal S; Williams S; Winter J; Tallman M; Gordon L; Frankfurt O; Evens A; Mehta J
Cancer; 2007 Apr; 109(8):1532-5. PubMed ID: 17351937
[TBL] [Abstract][Full Text] [Related]
18. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.
Pascual A; Csajka C; Buclin T; Bolay S; Bille J; Calandra T; Marchetti O
Clin Infect Dis; 2012 Aug; 55(3):381-90. PubMed ID: 22610925
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of voriconazole and the role of CYP2C19 genotype on treatment optimization in pediatric patients.
Hu L; Huang S; Huang Q; Huang J; Feng Z; He G
PLoS One; 2023; 18(9):e0288794. PubMed ID: 37695751
[TBL] [Abstract][Full Text] [Related]
20. Voriconazole exposure and the risk of cutaneous squamous cell carcinoma in allogeneic hematopoietic stem cell transplant patients.
Wojenski DJ; Bartoo GT; Merten JA; Dierkhising RA; Barajas MR; El-Azhary RA; Wilson JW; Plevak MF; Hogan WJ; Litzow MR; Patnaik MM; Wolf RC; Hashmi SK
Transpl Infect Dis; 2015 Apr; 17(2):250-8. PubMed ID: 25661996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
